Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
TFF Pharmaceuticals, Inc. (TFFP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 ARS Form ARS - Annual Report to Security Holders:
10/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/15/2023 8-K Quarterly results
Docs: "UNDERWRITING AGREEMENT",
"OPINION OF GREENBERG TRAURIG, LLP",
"TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock FORT WORTH, Texas, August 14, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or a...",
"TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock FORT WORTH, Texas, August 15, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it has priced its underwritten public offering of 19,896,000 shares of its common stock at a public offering price of $0.25 per share. All of the securities in the underwritten public offering are to be sold by the Company. The Company expects the gross proceeds from this offering to be $4.97 million, before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriter a 30-day option to purchase up to 2,984,400 add...",
"TFF PHARMACEUTICALS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Grant revenue $ 333,351 $ 28,004 $ 384,780 $ 95,439 Operating expenses: Research and development 2,681,898 5,102,090 6,700,557 10,339,514 General and administrative 2,670,363 3,678,119 5,789,579 6,891,317 Total operating expenses 5,352,261 8,780,209 12,490,136 17,230,831 Loss from operations Other income : Interest income 36,120 5,880 71,199 13,065 Change in fair value of note receivable - - Total other income , net 5,880 33,783 13,065 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 36,193,085 25,373,706 36,193,085 25,372,749 5 TFF PHARMACEUTICALS, INC. CON...",
"THE COMPANY'S CORPORATE UPDATE AND PRESENTATION MATERIALS"
08/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results"
04/06/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FIRST AMENDED AND RESTATED BYLAWS OF TFF PHARMACEUTICALS, INC."
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results"
02/14/2023 SC 13G/A Lung Therapeutics, Inc. reports a 2.1% stake in TFF Pharmaceuticals, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/09/2023 SC 13G/A CARLSON CAPITAL L P reports a 5.1% stake in TFF Pharmaceuticals, Inc.
01/11/2023 8-K Quarterly results
12/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
12/15/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
12/08/2022 8-K Quarterly results
11/28/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/23/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/18/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/18/2022 8-K Quarterly results
11/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
10/06/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/30/2022 8-K Quarterly results
09/21/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy